Alnylam Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	313.75	-278.16	-440.24	-1,131	-852.82
Depreciation & Amortization	55.66	56.67	54.05	44.47	89.69
Loss (Gain) From Sale of Investments	2.31	3.02	16.94	33.31	-55.7
Stock-Based Compensation	348.24	272.08	221.68	230.65	165.72
Other Operating Activities	248.92	152.15	194.46	273.84	174.24
Change in Accounts Receivable	-359.96	-86.55	-87.94	-45.6	-101.8
Change in Inventory	8.47	13.59	18.37	-34.14	-26.42
Change in Accounts Payable	75.07	91.09	80.84	191.77	88.24
Change in Unearned Revenue	-50.64	-235.45	55.02	-65.91	-50.4
Change in Other Net Operating Assets	-117.72	3.23	-9.03	-38.51	-72.45
Operating Cash Flow	524.08	-8.31	104.16	-541.27	-641.69
Capital Expenditures	-58.7	-34.28	-62.21	-72.06	-76.37
Investment in Securities	497.18	-63.25	-269.7	254.61	-192.56
Other Investing Activities	-2.15	-19.32	-4.44	-13.19	-4.36
Investing Cash Flow	436.33	-116.84	-336.35	169.35	-273.3
Long-Term Debt Issued	645.69	-	-	1,016	500
Long-Term Debt Repaid	-1,193	-	-	-880.72	-
Net Debt Issued (Repaid)	-546.95	-	-	135.39	500
Issuance of Common Stock	250.03	302.95	147.46	259.36	246.27
Other Financing Activities	-8.27	-8.79	24.67	31	500.85
Financing Cash Flow	-305.19	294.16	172.13	425.75	1,247
Foreign Exchange Rate Adjustments	34.94	-15.24	6.39	-7.43	-9.02
Net Cash Flow	690.16	153.77	-53.67	46.4	323.11
Free Cash Flow	465.38	-42.59	41.95	-613.33	-718.07
Free Cash Flow Margin	12.53%	-1.89%	2.29%	-59.12%	-85.05%
Free Cash Flow Per Share	3.46	-0.33	0.34	-5.04	-6.06
Cash Interest Paid	218.71	67.58	32.12	45.24	24.66
Cash Income Tax Paid	21.2	9.31	2.57	2.65	-
Levered Free Cash Flow	128.79	197.88	103.55	-444.35	97.11
Unlevered Free Cash Flow	286.68	286.54	179.32	-346.87	186.5
Change in Working Capital	-444.78	-214.08	57.26	7.62	-162.82

Updated Feb 12, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q